Dihydroergotamine Mesylate (Shin Nippon Biomedical Laboratories)

甲磺酸双氢麦角胺 (Shin Nippon Biomedical Laboratories)

Report date: 2025/05/12 16:47:13

Base Information

Drug NameDihydroergotamine Mesylate (Shin Nippon Biomedical Laboratories)
Drug Alias Name甲磺酸二氢麦角胺双氢麦角胺甲磺酸盐双氢麦角胺甲磺盐盐甲磺酸二氢有机胺双氢麦角胺 +[22] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1b (5-HT1b) receptor agonistsSerotonin 1d (5-HT1d) receptor agonists
TargetsSerotonin 1b (5-HT1b) receptorSerotonin 1d (5-HT1d) receptor
Therapy Area/IndicationsCluster HeadacheMigraine without AuraMigraine with Aura +[4] 
Global Approved IndicationsCluster HeadacheMigraine Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesShin Nippon Biomedical Laboratories Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSatsuma Pharmaceuticals Inc
Inactive CompaniesImpel PharmaceuticalsAllergan PlcBausch & Lomb (Singapore) Pvi Ltd
Active IndicationsMigraine without AuraMigraine with AuraMigraine Disorders
Inactive IndicationsCluster Headache

Other Information

ATC CodeN02CA01
Related LinksWikipediaDrugBankKEGG